PTC Therapeutics, Inc. (PTCT) AI Stock Analysis

PTC Therapeutics, Inc. is a biopharmaceutical company headquartered in South Plainfield, New Jersey, focused on the discovery, development, and commercialization of treatments for patients with rare disorders. The company leverages expertise in RNA biology and splicing modulation across clinical, pre-clinical, and research phases. Its commercial portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy across regions such as the United States, Brazil, Russia, and the European Economic Area. In addition, PTC Therapeutics commercializes Tegsedi and Waylivra in Latin America and the Caribbean, markets Evrysdi in Brazil for spinal muscular atrophy, and advances pipeline candidates like PTC518 for Huntington's disease.

Revenue delivered a 5-year CAGR of 35.4% from FY2020 to FY2025. Annual revenue expanded from $538.6M in FY2021 to $698.8M in FY2022 and $937.8M in FY2023, before declining 14.0% to $806.8M in FY2024. In FY2025, revenue increased 114.5% to $1.73B, producing net income of $682.6M and EPS of $7.60, compared to net income of -$363.3M in FY2024. Gross margin reached 95.9% and operating margin was 49.5% in FY2025. Over the trailing twelve months ended June 30, 2026, revenue was $1.01B with an operating margin of 41.3% and a profit margin of -3.8%, while quarterly revenue grew 101.5%.

As of June 30, 2026, PTC Therapeutics held $2.23B in cash and short-term investments against total debt of $696.5M, leaving net cash of $1.53B. Total assets stood at $3.25B with a current ratio of 3.39, while shareholders' equity was -$165.4M. In FY2025, the company produced operating cash flow of $711.2M and free cash flow of $411.2M after capital expenditures of $300.0M. The company's share count grew 30.2% over 5 years.

At a last close of $59.24, PTC Therapeutics had a market cap of $4.94B and an enterprise value of $3.67B. The stock traded at a forward P/E of 22.7x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio was 4.9x compared to the peer median of 4.1x, and EV-to-EBITDA was 21.2x versus the peer median of 12.0x. Over the past year, PTCT fell 11.3%, trailing the S&P 500 (SPY) return of 16.8%. Over 5 years, the stock rose 55.5%, while SPY gained 83.0%.

Wall Street analysts rate the stock with 9 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 1 Strong Sell recommendations. The mean price target of $97.94 represents potential upside of 65.3% over the last close of $59.24. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $1.52 on revenue of $1.26B. The company beat EPS estimates in 3 of the last 4 quarters. The next earnings date is October 29, 2026.

This page is an AI-written research summary of PTC Therapeutics, Inc. (PTCT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PTCT income statement, PTCT balance sheet, PTCT key metrics, PTCT analyst forecast, PTCT chart. See the PTCT stock overview for the latest quote and news.